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Glycopeptide dendrimers as Pseudomonas aeruginosa
biofilm inhibitors†
Jean-Louis Reymond,* Myriam Bergmann and Tamis Darbre
Synthetic glycopeptide dendrimers composed of a branched oligopeptide tree structure appended with
glycosidic groups at its multiple N-termini were investigated for binding to the Pseudomonas
aeruginosa lectins LecB and LecA. These lectins are partly responsible for the formation of antibiotic
resistant biofilms in the human pathogenic bacterium P. aeruginosa, which causes lethal airway
infections in immune-compromised and cystic fibrosis patients. Glycopeptide dendrimers with high
aﬃnity to the lectins were identified by screening of combinatorial libraries. Several of these
dendrimers, in particular the LecB specific glycopeptide dendrimers FD2 and D-FD2 and the LecA
specific glycopeptide dendrimers GalAG2 and GalBG2, also eﬃciently block P. aeruginosa biofilm
formation and induce biofilm dispersal in vitro. Structure–activity relationship and structural studies are
reviewed, in particular the observation that multivalency is essential to the anti-biofilm eﬀect in these
dendrimers.
1. Introduction
The spread of antibiotic resistant bacteria is one of the most
pressing problems in human health today. The ubiquitous
Gram-negative bacterium Pseudomonas aeruginosa infects immune-
compromised and cystic fibrosis patients and causes lethal
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airway infections.1 The formation of bacterial communities
attached to biotic or abiotic surfaces, the so-called process of
biofilm formation, forms a physical barrier to antibiotics and
allows antibiotic resistance. Disrupting this process can restore
antibiotic sensitivity and overcome resistance.2 Biofilm for-
mation is mediated in part by the galactose-specific lectin LecA
(PA-IL)3 and the fucose-specific lectin LecB (PA-IIL).4 Deletion
mutants lacking the lecA or lecB gene showed impaired biofilm
formation,5 suggesting that the inhibition of the corresponding
lectins might lead to biofilm inhibition and a therapeutic eﬀect
in controlling P. aeruginosa infections.
Lectins are ubiquitous carbohydrate-binding proteins with
specific but often weak binding sites, whose potency is
increased by multivalency leading to the so-called cluster
eﬀect.6 Multivalency occurs both on the side of the lectin
(e.g. both LecA and LecB are tetrameric with four identical
carbohydrate binding sites)7 and on the side of the glycosidic
ligand such as multiply glycosylated glycoproteins. A variety of
synthetic glycoclusters8 have been investigated for inhibiting
LecA,9 LecB,10 or both,11 and in selected cases for their eﬀects
in controlling P. aeruginosa infections in vivo.12 This review
focuses on a related eﬀort to develop inhibitors of LecA and
LecB on the basis of glycopeptide dendrimers.13
Dendrimers are regularly branched synthetic macro-
molecules14 particularly well suited for multivalent display of
chemical groups and displaying useful properties for a broad
range of applications such as catalysis15 and biomedical16
applications, including the multivalent display of carbo-
hydrates for lectin binding.17 While most dendrimers are built
of organic polymer building blocks, peptide dendrimers are
assembled from proteinogenic amino acids using diamino
acids such as lysine as branching points,18 which generates a
protein-like structure whose properties can be fine-tuned by
varying the length and composition of the peptide arms
throughout the structure. Advantages of peptide dendrimers
over most other dendrimers include: (a) a straightforward and
modular synthesis by solid-phase peptide synthesis (SPPS) from
commercially available building blocks yielding pure products
rather than polymeric mixtures, (b) the possibility of tuning
properties such as water solubility, hydrophobicity and charges
by varying amino acids, and (c) a low potential for toxicity
when applied in vivo due to the use of natural amino acid
building blocks, although immunogenicity must be considered.
Disadvantages include: (a) a relatively expensive synthesis by
SPPS limited to multimilligram amounts at the research stage
and (b) a high conformational flexibility given by the nature of
the building blocks.
Appending the peptide arms with a glycosidic ligand within
a combinatorial library set-up led to the discovery of the
fucosylated peptide dendrimer FD2,19 a tetravalent ligand
binding to the fucose-specific lectin LecB, and the related
galactosylated dendrimers GalAG2 and GalBG2, which target
the galactose specific lectin LecA. These dendrimers are potent
P. aeruginosa biofilm inhibitors (Fig. 1).20,21 Structure–activity
relationship studies show that multivalency is crucial for bio-
film inhibition and dispersal with these ligands.
2. Peptide dendrimers
2.1. Solid-phase peptide synthesis
Most dendrimers are symmetrical molecular trees consisting of
a conserved branching network assembled from repetitive
dendrons, on which functional end groups are grafted in a
multivalent manner. We recently introduced a new class of
dendrimers assembled from amino acid building blocks by
solid-phase peptide synthesis.22 In these dendrimers the
branches consist of variable amino acids connected by diamino
acid branching points. Under optimized conditions using a
relatively low resin loading (0.2 mmol g1) and double coupling
(carrying out the peptide coupling step twice for each residue),
the approach gives pure products in good isolated yields up to
third generation dendrimers with eight end groups, typically
containing 37 residues after 11 coupling cycles. In the divergent
approach of SPPS, all arms are grown simultaneously, however
orthogonal protection can yield asymmetric sequences.23
Larger peptide dendrimers containing up to 341 amino acids
and 64 end groups can be obtained by convergent ligation
assembly24 of smaller peptide dendrimer building blocks using
the multivalent thioether formation between multiple N-terminal
chloroacetamide groups of a ‘‘core’’ dendrimer and the thiol
Fig. 1 Structures of P. aeruginosa biofilm inhibitors FD2, GalAG2 and GalBG2.
FD2 targets LecB, GalAG2 and GalBG2 both target LecA. Peptides written with
one-letter codes for amino acids, K is a branching lysine with peptide chains
extending at both the a- and the e-amino groups. The C-terminus at the core is
CONH2.
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group of a cysteine residue as the first residue of another peptide
dendrimer, the so-called ClAc ligation.25 Initial studies with
enzyme models highlighted multivalency eﬀects of histidine in
esterase dendrimers,26–28 and of N-terminal proline in aldolase
dendrimers.29
2.2. Combinatorial libraries of protein-like peptide dendrimers
The possibility of varying amino acid side chains throughout the
peptide dendrimer allows one to performmutational adaptations
similar to those in proteins and peptides. By selecting amino
acids, one can define key properties such as defined ratios of
hydrophilic and hydrophobic groups to promote solubility in
various media, or the presence of key functional groups to enable
binding or catalysis. Fine-tuning of these desirable properties
can be reached by systematic variations using combinatorial
chemistry capitalizing on split-and-mix synthesis of one-bead–
one-compound libraries, the founding paradigm of combina-
torial chemistry initially developed for linear peptides.30 We
introduced two new features to the SPPS protocol that rendered
the combinatorial method more user friendly: (1) the decoding
of the dendrimer sequence on polymer beads by amino acid
analysis, which is an inexpensive, reliable and fast analytical
method suitable to sequence hundreds of beads, a method
which we later also adapted for linear peptides;31 (2) simplified
on-bead and oﬀ-bead assays enabling fast and reliable identifi-
cation of positive hits with various fluorescence assays.32,33
This combinatorial approach was successfully employed for
the identification of cobalamin ligands,34,35 various dendritic
esterases36 and aldolase enzyme models,37 iron binding pep-
tide dendrimers38 and antimicrobial peptide dendrimers.39
Peptide dendrimers mimic natural proteins by the nature of
their building blocks. The combinatorial library approach
extends the analogy by making it possible to evolve the peptide
dendrimers by sequence optimization, recapitulating the
natural evolution of proteins by mutations and selection cycles.
Although the peptide dendrimer sequence space is much
smaller than that of a real protein, the dendritic topology
avoids the necessity of folding by forcing the peptide dendrimer
to adopt a globular structure. The dendritic architecture results
in disordered conformations resembling the molten globule
state of proteins,40–42 with a dynamic tertiary structure con-
taining few native-like secondary structure elements such as
a-helices and b-sheets.43 In contrast to proteins, peptide
dendrimers are entirely stable towards denaturation. The
susceptibility of a peptide dendrimer towards proteolysis can
be controlled by the degree of branching. Peptide dendrimers
with three amino acids between the branching points may
undergo proteolysis at protease cleavage sites, whereas only
one amino acid between the branching points leads to com-
plete resistance against proteases.44
3. Glycopeptide dendrimers
3.1. Synthesis of glycopeptide dendrimers
Peptide dendrimers can be used tomimic glycoproteins by attaching
glycosidic groups at the end of the peptide dendrimer branches.
Since the peptide dendrimer topology is in itself non-natural,
we did not use the natural N- and O-glycosidic linkages but
rather a more simple attachment chemistry compatible with
SPPS and potentially high-yielding. Two approaches were inves-
tigated: (1) the oxidative cleavage of N-terminal serine residues
with sodium periodate to generate a glyoxamide end group
suitable for oxime ligation with an oxyamine-functionalized
carbohydrate;45,46 (2) amidation of the multiple N-termini of
the peptide dendrimer with a peracetylated glycoside containing
a free carboxylic acid on the aglycone, followed by resin
deacetylation by basic methanolysis prior to acidic cleavage.
The two approaches were tested in a study of glycopeptide
dendrimers as drug delivery dendrimers for colchicine,47,48
which showed that the amidation protocol as the last step of
SPPS was the more practical method to prepare glycopeptide
dendrimers. The approach was also applied to prepare con-
canavalin A ligands.49
3.2. Selection of fucose lectin inhibitors from combinatorial
libraries
Our initial approach to glycopeptide dendrimer lectin ligands
was inspired by previous examples of combinatorial glyco-
peptide libraries.50 In particular we used a previously reported
enzyme-linked lectin assay (ELLA) to visualize binding of
lectins to SPPS beads to identify binding sequences in a
combinatorial library.50c A 150625-member library L1 of G2
dendrimers with three amino acids per branch and lysines as
branching diamino acids was prepared on tentagel beads and
acylated at their N-termini with a-C-fucosyl-acetic acid 1 (Fig. 2).
Amino acids were distributed in six variable positions to allow
positive, negative, hydrophobic, small and polar or aromatic
residues throughout the sequence, using each amino acid twice
at two positions in successive branches to allow decoding by
amino acid analysis.32 The library was assayed for binding to
the fucose-specific lectin UEA-I lectin in the presence of 3 M
free L-fucose, which reduced staining from 90% of the beads to
less than 2% of the beads, allowing us to pick selective hits. The
critical role of L-fucose was evidenced by the absence of lectin
binding to the control N-acetylated dendrimer library.
A selection of hit sequences were resynthesized and their
lectin binding characterized in detail by ELLA,51 which identi-
fied hit FD2 as the most potent ligand with an IC50 = 11 mM
towards lectin UEA-I and a relative potency of 115 in reference
to L-fucose, corresponding to a six-fold aﬃnity enhancement
per fucosyl group. Although the multivalency eﬀect observed
with FD2 was modest, it was confirmed by the observation of
much weaker binding in the divalent and monovalent glyco-
peptide analogs of the dendrimer. Valency variations in a
dedicated library further confirmed that strong binding
required at least four carbohydrate groups on the dendrimer.52
In subsequent combinatorial experiments,53 the fucosylated
dendrimer library used to discover FD2 was rescreened using a
recombinant P. aeruginosa LecB54 labelled with rhodamine B
instead of UEA-I with the hope of identifying even stronger
LecB ligands. Screening was performed with a 0.45 M fucose
competitor in the presence of 1% bovine serum albumin to
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reduce non-specific binding. Beads retaining an intense fluores-
cent ring after extensive washing with fucose were considered
as positive hits. These dendrimers contained predominantly
cationic sequences similar to those identified using lectin
UEA-I. Thus, six out of nine sequences carried multiple posi-
tively charged residues (Lys at X6 or Arg at X5). These positive
charges do not seem to interact with the lectins, and might
have been selected in the library experiment for providing good
water solubility and allowing a favourable orientation of the
glycosyl groups for lectin binding. On the other hand, one
sequence was neutral and one was anionic, suggesting that
charged side chains might not be necessary for optimal binding
to LecB. Functionalizing the peptide dendrimer library with
4-carboxyphenyl-a-L-fucoside 2 at the N-termini to form library
L2 followed by screening yielded several new glycopeptide
dendrimers such as PA8 and PA9 binding to LecB with com-
parable strength to FD2.55 However these dendrimers were less
soluble than FD2 due to their more hydrophobic carboxyphenyl
aglycone, and also did not yield substantially stronger biofilm
inhibition eﬀects.
Comparison of a series of dendrimers identified by screening
as well as further multivalency variations showed that binding
was strongly influenced by multivalency and by the presenta-
tion of the carbohydrate by the peptide backbone. An overview
of the binding properties of fucosylated glycopeptide dendri-
mers to LecB as determined by ELLA is shown in Table 1. One
particularly striking result was the observation of a very strong
binding with dendrimer 2G3, an octavalent analogue of FD2,
and simultaneously of a significantly weaker binding for its
analog 2G30 where the branching lysine residues were replaced by
the more compact Dap (2,3-diaminopropanoic acid) branching
amino acid. Interestingly, the positioning of the branching
diamino acid was critical to binding, as illustrated by the
observation that dendrimer PA10b, with the G2 branching
point moved by one position inward to allow a more flexible
and potentially further reaching the outer tetrapeptide arm,
actually lost one order of magnitude in binding compared to
the parent sequence PA10.
3.3. Biofilm inhibition with LecB ligands
The P. aeruginosa lectin LecB plays a role in biofilm formation, as
evidenced by the impaired biofilm formation in DLecB mutant
strains and in the partial inhibitory eﬀect of p-nitrophenyl
fucoside (NPF) on wild type biofilms but not on DLecB biofilms.
Glycopeptide dendrimer FD2 and analogs were evaluated for
biofilm inhibitory activity against P. aeruginosa biofilms using
the steel coupon assay.56 In this assay bacterial biofilms are
grown on stainless steel coupons and stained with acridine
orange. At a concentration of 50 mM, all tested dendrimers were
able to reduce biofilm formation significantly, but only FD2
inhibited biofilm formation completely. All dendrimers were
also tested for their ability to disperse already existing biofilms,
which is more similar to the in vivo situation. In both the
biofilm inhibition and the dispersal assay, all the dendrimers
showed a remarkable activity. The eﬀect was much stronger
than with the monovalent control a-NPF. The high biofilm
inhibitory activity of FD2 was also observed on several clinical
isolates of P. aeruginosa. FD2 did not show any eﬀect on the
Fig. 2 Synthesis and structure of glycopeptide dendrimer combinatorial libraries
L1 and L2 used to identify FD2.
Table 1 ELLA data for binding to LecBa
Cpd nb Sequence IC50 (mM) Rel. pot.
c Fucosed
L-Fucose 1 — 11 1.0 1.0
2G0 1 cFuc-KPL 5.9 1.9 1.9
2G1 2 (cFuc-KPL)2KFKI 2.7 4.1 2.0
FD1 4 (cFuc-KHV)4(KHGA)2KHI 0.43 26 6.4
FD2 4 (cFuc-KPL)4(KFKI)2KHI 0.14 79 20
FD3 4 (cFuc-KHL)4(KGKI)2KHI 0.19 58 15
FD4 4 (cFuc-KRD)4(KSRA)2KHI 0.54 20 5.1
FD9 4 (cFuc-SPD)4(KEVA)2KHI 0.63 18 4.4
FD10 4 (cFuc-ETD)4(KTGA)2KHI 0.25 44 11
PA5 4 (cFuc-GRV)4(KEGL)2KHI 0.75 15 3.7
PA6 4 (cFuc-GTV)4(KHPT)2KHI 0.30 37 9.2
PA7 4 (cFuc-GHT)4(KTGD)2KHI 0.28 39 9.8
PA8 4 (OFuc-KAD)4(KSGA)2KHI 0.11 100 25
PA9 4 (OFuc-EHD)4(KEVA)2KHI 0.35 31 7.8
PA10 4 (cFuc-GTV)4(KHPT)2KHI 0.21 52 13
PA10b 4 (cFuc-GTVH)4(KPT)2KHI 2.4 4.6 1.1
PA11 4 (cFuc-EHY)4(KYGD)2KHI 0.26 42 11
2G3 8 (cFuc-KP)8(KLF)4(KKI)2KHI 0.025 440 55
2G30 8 (cFuc-KP)8(BLF)4(BKI)2BHI 0.94 12 1.5
10G3 8 (cFuc-ET)8(KDY)4(KGA)2KHI 0.12 92 12
a Linear peptide notation from N- to C-terminus as CONH2 using one-
letter codes for amino acids, K denotes a branching lysine and B a
branching L-2,3-diaminopropanoic acid with both amino groups
acylated, cFuc: c-fucoside from building block 1, OFuc: O-fucoside from
building block 2; binding data from ELLA; all assays were run in
triplicate. b n is the number of fucosyl groups in the ligand. c Rel.
pot. = relative potency = IC50(fucose)/IC50(ligand).
d Rel. pot. per
fucose = rel. pot./n.
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deletion mutant DLecB, giving evidence that the biofilm inhi-
bitory eﬀect is LecB-mediated.
Since FD2 contains several protease cleavage sites and is
conformationally flexible, we synthesized D-FD2 (cFuc-kpl)4-
(Kfki)2Khi-NH2, a stereoisomer of FD2 containing D-amino
acids, with the hope of obtaining an analog retaining biological
activity but more stable towards proteolytic degradation.57 The
aﬃnity of D-FD2 to LecB determined by ELLA was 5-fold weaker
than that of FD2, indicating that the amino acid chirality has
some influence on binding aﬃnity, an eﬀect accompanied by a
smaller secondary structure content as measured by CD and a
less compact structure compared to FD2 as measured by the
hydrodynamic radius. Nevertheless D-FD2 showed similar
potency in inhibiting the biofilm formation of P. aeruginosa
strain PAO1 and was also able to disperse already existing
biofilms. When tested on clinical isolates of P. aeruginosa,
D-FD2 was however less active than FD2 (Fig. 3). Proteolytic
treatment of D-FD2 with trypsin or chymotrypsin for 48 h
showed no degradation, whereas FD2 was completely degraded
after 30 min under the same conditions. D-FD2 was also stable
in human serum.
3.4. LecA ligands and biofilm inhibitors
Since FD2 was identified as being a high-aﬃnity ligand to the
fucose-specific lectin LecB and a potent P. aeruginosa biofilm
inhibitor, we tested if the peptide sequence of FD2 may also be
suitable for inhibitors of the galactose-specific P. aeruginosa
lectin LecA. Considering that galactosides with hydrophobic
groups at the sugar anomeric position show enhanced aﬃnity
to LecA,58 the 4-carboxy-phenyl b-galactoside (GalA) was used as
a galactosyl group at the terminus. To evaluate the eﬀect of the
linker to aﬃnity, a second set of glycopeptide dendrimers bearing
carboxypropyl-b-thiogalactoside (GalB) as an N-terminal glyco-
side was also prepared. For a better understanding of the eﬀect
of multivalency on binding, the monovalent linear tripeptide
arms GalA/BG0 and the divalent dendrimers GalA/BG1 were
also considered. Characterization of the binding interaction of
LecA with the various ligands by hemagglutination inhibition
assay59 and isothermal titration calorimetry indicated a strong
multivalency eﬀect on both the GalA and the GalB series
(Table 2). The tetravalent dendrimer GalAG2 showed the stron-
gest binding.
The LecA specific glycopeptide dendrimers not only bound
tightly to LecA, but also inhibited P. aeruginosa biofilms (Fig. 4).
The G2 dendrimers showed strong biofilm inhibition, while
the lower multivalency analogs and the control N-acetylated
dendrimers were essentially inactive. The strong biofilm inhibition
by GalBG2, a relatively weak but tetravalent ligand, showed that
multivalency was essential for biofilm inhibition, while the
actual binding constant was not essential. These data were
consistent with a LecA-mediated inhibition of P. aeruginosa
biofilms by the dendrimers.
Fig. 3 P. aeruginosa biofilm inhibition assay. (A) Inhibition of P. aeruginosa
PAO1 biofilms. (B) Biofilm inhibition of PAO1 and three P. aeruginosa clinical
isolates. Biofilm inhibition was performed using the steel coupon assay on the
wild-type strain PAO1 without additive (Ref.), or with added a-NPF (0.5 mM) or
dendrimers (0.05 mM). See ref. 57 for details.
Table 2 Hemagglutination assay and ITC data for binding to LecAa
Ligand Name or sequence n
MIC
(mM) r.p./n
Kd
(mM) r.p./n
D-Gal D-Galactose 1 3100 1 88 1
NPG p-Nitrophenyl-b-galactoside 1 550 6 14 6
IPTG Isopropyl-b-thiogalactoside 1 1100 3 32 3
GalAG0 GalA-KPL 1 80 40 4.2 20
GalAG1 (GalA-KPL)2KFKI 2 31 50 0.5 90
GalAG2 (GalA-KPL)4(KFKI)2KHI 4 0.8 1000 0.10 220
GalBG0 GalB-KPL 1 2500 1.3 52 1.7
GalBG1 (GalB-KPL)2KFKI 2 630 2.5 2.1 20
GalBG2 (GalB-KPL)4(KFKI)2KHI 4 130 13 0.4 60
a Peptide sequences indicated with one-letter codes for amino acids, K =
branching lysine. The C-terminus in CONH2. MIC = minimal inhibitory
concentration for the hemagglutination assay. n = number of galactose
residues per ligand, r.p./n = relative potency per galactose residue =
(MIC(D-galactose)/MIC(ligand))/n or (Kd(D-galactose)/Kd(ligand).)/n.
Fig. 4 Inhibition of P. aeruginosa biofilms by glycopeptide dendrimers binding
to LecA. Biofilm assays were performed using the steel coupon assay56 at 20 mM
galactose endgroup concentration.
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3.5. Structural studies
Structural studies were carried out to gain an insight into the
interaction of the tetravalent glycopeptide dendrimers FD2,
GalAG2 and GalBG2 with their lectins. While crystallization
attempts with the tetravalent dendrimers and the lectins all
failed, single crystals were obtained for complexes of the
terminal tripeptides 2G0 in complex with LecB,20 and GalAG0
and GalBG0 in complex with LecA.21 In these structures the
terminal glycosidic group was observed to bind at the expected
position. In the case of the LecB complex with 2G0 and the LecA
complex with GalBG0 the tripeptide portion of the ligands was
disordered. In the case of GalAG0 however, the tripeptide was
well resolved. The most striking interaction concerned the
interaction of the 4-carboxyphenyl group with residues His50
on the lectin, which interacted via a histidine-T-stack inter-
action. This interaction, which probably explains the stronger
binding of aromatic galactosides to LecA, was also observed in
the corresponding nitrophenyl galactoside LecA complex and
was unprecedented for ligand–protein interactions.21
Lectins LecA and LecB both have a typical tetrameric struc-
ture with four carbohydrate binding sites. Multivalency eﬀects
on lectin binding are often interpreted in terms of a multivalent
ligand binding simultaneously to two or more carbohydrate
binding sites on the same lectin. A molecular dynamics (MD)
study was carried out to gain an insight into the possible cause
of the multivalency eﬀects that might explain the stronger
binding of FD2 to LecB and GalA/BG2 to LecA as compared to
their monovalent ligands. Models of the dendrimers bound to
their respective lectin were constructed by fusing the MD
simulated dendrimer structures with the experimentally deter-
mined tripeptide–lectin complexes 2G0.LecB, GalAG0.LecA and
GalBG0.LecA, followed by energy minimization and simula-
tions for 10 ns. In all three cases the dendrimer arms were
clearly too short to enable bridging between two carbohydrate
binding sites on the same lectin tetramer, ruling out chelation
type multivalency eﬀects as a cause for the increased binding
(Fig. 5).
The structural models provided an insight into the interactions
of the glycopeptide dendrimers with their lectin. In all cases
protein–ligand contacts were visible outside the carbohydrate
binding site, some of which were also confirmed in docking
studies with the terminal tripeptides.53 Such contacts probably
explain the fact that the amino acid sequence of the glyco-
peptide dendrimers significantly influences lectin binding as
observed in the extensive study with various glycopeptide
dendrimer ligands to LecB (Table 1). On the other hand
the structures cannot explain the biofilm inhibition eﬀect
observed, in particular the fact that several strong binding
tetravalent ligands such as PA5 and PA6 (binding LecB) fail to
exert a significant eﬀect on the biofilm, while other weaker
ligands such as GalBG2 (binding LecA) are potent biofilm
inhibitors. One possibility of explaining these discrepancies
might involve localization eﬀects relative to the site of action of
the lectins.60 The formation of supramolecular aggregates
might also play a role. Indeed both LecA and LecB are believed
to enable tissue attachment and biofilm formation by multi-
valent cross-linking between glycosidic groups on the bacterial
surface and in the tissues. Certain multivalent lectin ligands
might lead to the formation of insoluble aggregates that
eﬀectively take the lectins out of the system, while others could
act as cross-linking agents between lectins to form a higher
multivalency complex still capable of acting as a cross-linking
lectin and therefore promoting biofilm formation. Additional
studies will be required to explain the biofilm inhibition
mechanism of the glycopeptide dendrimers.
4. Conclusion and outlook
A straightforward and easily tunable SPPS and combina-
torial library approach to glycopeptide dendrimers was imple-
mented to rapidly discover potent multivalent ligands to the
P. aeruginosa lectins LecA and LecB. Variations in branching
sequences and multivalency were carried out leading to an
extensive structure–activity landscape for lectin binding.
Further optimizations are in progress concerning the nature
of the tripeptide arms in contact with the lectin and the degree
of multivalency as possibilities to increase lectin binding and
biofilm inhibition.
Fig. 5 Models of glycopeptide dendrimer lectin complexes obtained from MD simulations. The protein is shown in cartoon representation and the glycopeptide
dendrimers in CPK. The Ca2+ ions are shown in magenta and indicate the location of the carbohydrate binding sites.
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Many questions are still open concerning the biofilm inhibi-
tion eﬀect observed with the glycopeptide dendrimers.
While multivalency is clearly crucial to obtain biofilm inhibi-
tion, strong binders are not necessarily good biofilm inhibi-
tors, which might indicate the formation of lectin complexes
still functional for promoting biofilm formation. Biofilm
inhibition might also depend on localization of the ligand
within the biofilm and not only on binding. Further
studies will be necessary to identify the site of action of the
lectin inhibitors. Potency optimization will also be required by
further amino acid and valency variation to reach sub-
micromolar levels not only in lectin binding but also in biofilm
inhibition.
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